Abstract
In the diagnosis of HCC, US and sonazoid-enhanced US are more useful for characterizing hepatic tumors than multidetector-row computed tomography (MDCT). Gd-EOB DTPA is a new contrast medium for MRI. In the hepatobiliary phase, 90% of HCCs are detected as low intensity areas. Sorafenib is a multikinase inhibitor that is already used for renal cell carcinoma. In the SHARP trial, sorafenib was established as the first choice of treatment for standard of care advanced HCC patients with preserved liver function.
